The Channel 7 Telethon Trust is a registered charitable trust that has a philosophy to financially support the medical and social welfare of children and young people, and to fund research into children’s diseases.
Since the first Telethon on Channel 7 on November 29 1968, Telethon has raised over $268 million and provided much needed financial assistance to a significant number of charitable organisations, children's hospitals & research/medical facilities in Western Australia.
WIRF received their first grant from Telethon 40 years ago to purchase a new piece of technology called ‘a computer’ which was shipped in parts from Germany. Since this time the Channel 7 Telethon Trust has been an avid supporter of WIRF and our work.
Last year WIRF was honoured to receive funding support for several research projects from the Channel 7 Telethon Trust. These studies focussed on improving the health and outcomes of WA neonates and infants from pregnancy to childhood.
STUDIES SUPPORTED BY CHANNEL 7 TELETHON TRUST
Neurodevelopmental outcomes of preterm neonates who received probiotic supplementation: Follow-up of a randomised-controlled trial
Dr Sachin Agrawal, Professor Sanjay Patole
This study will assess not only the safety of probiotics in terms of long-term neurodevelopment in very preterm infants, but also their potential for reducing the risk of neuropsychiatric disorders such as ASD and ADHD. Further trials could be undertaken if the study results indicate the potential benefits of probiotics in this field.
Solithromycin treatment for premature rupture of membranes: a randomised controlled trial
Professor John Newnham, Dr Scott White, Professor Jeff Keelan
This study aims to determine whether Solithromycin treatment of women with Preterm prelabour rupture of the membranes (PPROM) improves maternal and neonatal outcomes compared to the current standard treatment with erythromycin. Further, the study aims to assess the pharmacokinetics of solithromycin in human pregnancy. The primary outcome will be delay of delivery for at least 48 hours; secondary outcomes will be neonatal respiratory, infectious, and neurological morbidity and maternal infectious morbidity.
Effect of single versus multi-strain probiotic supplementation (SiMPro) on the time to full enteral feeds in preterm neonates – a double blind randomised controlled trial
Dr Gayatre Jape, Professor Sanjay Patole
Given the importance of understanding the complex interactions of early intestinal microbiome and long-term outcomes, this study has sought to carry out advanced metagenomics studies on the infants enrolled in the SiMPRO trial to allow the study team to characterise the effects of the two probiotic regimens on the gut microbiome. This will also allow the team to clarify just how the probiotics exert their beneficial effects and understand how to improve therapy and outcomes.
Pre-clinical trial of Ex-vivo uterine environment (EVE) therapy for extremely preterm infants
Associate Professor Matt Kemp
EVE therapy is a life-support platform for extremely preterm infants. It has the advantage of eliminating the need to stress the extremely immature preterm lung with mechanical ventilation. Rather, EVE therapy treats the extremely preterm infant as a fetus. The specific aim of this study is to perform a long-term (14 day) pre-clinical study of the EVE therapy system in order to further refine it towards clinical application.
WA Pregnancy Biobank: Phase II
Professor Jeff Keelan, Associate Professor Craig Pennell, Professor Dorota Doherty
This study will support the continued recruitment, sampling and curation of the WA Pregnancy Biobank (WAPB), which was initially funded by Channel 7 Telethon Trust in 2014 and which plays a central role in the WA Preterm Birth Prevention Initiative’s research aims to lower the rate of preterm birth throughout the state. Specifically, Phase II will employ research midwives and research assistants, plus sampling-related consumables, to continue the expansion of the Biobank to a size that will enable it to address questions relating to preterm birth treatment efficacy and targeting.